AdlerLE, HofferLD, WiserA, FreedmanR. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry, 150:1856–1861. 1993.
2.
BejerotS, NylanderL. Low prevalence of smoking in patients with autism spectrum disorders. Psychiatry Res, 119:177–82. 2003.
3.
CarlssonML. On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry, 25:5–26. 2001.
4.
ChengSB, AmiciSA, RenXQ, McKaySB, TreuilMW, LindstromJM, RaoJ, AnandR. Presynaptic targeting of alpha4beta 2 nicotinic acetylcholine receptors is regulated by neurexin-1beta. J BiolChem, 284,23:251–232592009.
CourchesneE, PierceK, SchumannCM, RedcayE, BuckwalterJA, KennedyDP, MorganJ. Mapping early brain development in autism. Neuron, 56:399–413. 2007.
8.
CouryD. Medical treatment of autism spectrum disorders. Curr OpinNeurol, 23:131–136. 2010.
9.
DalackG W, BecksL, HillE, PomerleauOF, Meador–WoodruffJH. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology, 21:195–202. 1999.
10.
DavisJA, GouldTJ. Atomoxetine reverses nicotine withdrawal-associated deficits in contextual fear conditioning. Neuropsychopharmacology, 32:2011–2019. 2007.
11.
FombonneE. The epidemiology of autism: A review. Psychol Med, 29:769–786. 1999.
12.
FrazierCJ, BuhlerAV, WeinerJL, DunwiddieTV. Synaptic potentials mediated via alpha-bungarotoxin-sensitive nicotinic acetylcholine receptors in rat hippocampal interneurons. J Neurosci, 18:8228–8235. 1999a.
13.
FrazierCJ, RollinsYD, BreeseCR, LeonardS, FreedmanR, DunwiddieTV. Acetylcholine activates an alpha-bungarotoxin-sensitive nicotinic current in rat hippocampal interneurons, but not pyramidal cells. J Neurosci, 18:1187–1195. 1999b.
14.
GeschwindDH. Advances in autism. Annu Rev Med, 60:367–380. 2009.
15.
GunnellD, IrvineD, WiseL, DaviesC, MartinRM. Varenicline, suicidal behaviour: A cohort study based on data from the General Practice Research Database. BMJ, 339:b3805. 2009.
MihalakKB, CarrollFI, LuetjeCW. Varenicline is a partial agonist at alpha4 beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol, 70:801–805. 2006.
23.
MineurYS, PicciottoMR. Nicotine receptors and depression: Revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci, 31:580–586. 2010.
24.
MiwaJ M, FreedmanR, LesterHA. Neural systems governed by nicotinic acetylcholine receptors: Emerging hypotheses. Neuron, 70:20–33. 2011.
25.
NewhousePA, KeltonM. Nicotinic systems in central nervous systems disease: Degenerative disorders and beyond. Pharm Acta Helv, 74:91–101. 2000.
26.
NewhouseP, SinghA, PotterA. Nicotine and nicotinic receptor involvement in neuropsychiatric disorders. Curr Top Med Chem, 4:267–282. 2004.
27.
NiauraR, JonesC, KirkpatrickP. Varenicline. Nat Rev Drug Discov, 5:537–538. 2006.
28.
PapkeRL, Trocmé–ThibiergeC, GuendischD, Al RubaiySA, BloomSA. Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists. J Pharmacol Exp Ther, 337:367–379. 2011.
29.
PasquiniM, GaraviniA, BiondiM. Nicotine augmentation for refractory obsessive-compulsive disorder. A case report. Prog Neuropsychopharmacol Biol Psychiatry, 29:157–159. 2005.
30.
PerryEK, LeeML, Martin–RuizCM, CourtJA, VolsenSG, MerritJ, FollyE, IversenPE, BaumanML, PerryRH, WenkGL. Cholinergic activity in autism: Abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry, 158:1058–1066. 2001.
31.
RamockiMB, ZoghbiHY. Failure of neuronal homeostasis results in common neuropsychiatric phenotypes. Nature, 455:912–918. 2008.
32.
SanbergPR, SilverAA, ShytleRD, PhilippMK, CahillDW, FogelsonHM, McConvilleBJ. Nicotine for the treatment of Tourette's syndrome. Pharmacol Ther, 74:21–25. 1997.
33.
SargentPB. The diversity of neuronal nicotinic acetylcholine receptors. Ann Rev Neurosci, 16:403–443. 1993.
34.
SüdhofTC. Neuroligins and neurexins link synaptic function to cognitive disease. Nature, 455:903–911. 2008.
35.
WilensTE, BiedermanJ, SpencerTJ, BosticJ, PrinceJ, MonuteauxMC, SorianoJ, FineC, AbramsA, RaterM, PolisnerD. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry, 156:1931–1937. 1999.
36.
ZhangZW, CogganJS, BergDK. Synaptic currents generated by neuronal acetylcholine receptors sensitive to alpha-bungarotoxin. Neuron, 17:1231–1240. 1996.
